The Influences of Pore Blockage by Natural Organic Matter and Pore Dimension Tuning on Pharmaceutical Adsorption onto GO-Fe3O4

The ubiquitous presence of pharmaceutical pollution in the environment and its adverse impacts on public health and aquatic ecosystems have recently attracted increasing attention. Graphene oxide coated with magnetite (GO-Fe3O4) is effective at removing pharmaceuticals in water by adsorption. However, the myriad compositions in real water are known to adversely impact the adsorption performance. One objective of this study was to investigate the influence of pore blockage by natural organic matter (NOM) with different sizes on pharmaceutical adsorption onto GO-Fe3O4. Meanwhile, the feasibility of pore dimension tuning of GO-Fe3O4 for selective adsorption of pharmaceuticals with different structural characteristics was explored. It was shown in the batch experiments that the adsorbed pharmaceutical concentrations onto GO-Fe3O4 were significantly affected (dropped by 2–86%) by NOM that had size ranges similar to the pore dimensions of GO-Fe3O4, as the impact was enhanced when the adsorption occurred at acidic pHs (e.g., pH 3). Specific surface areas, zeta potentials, pore volumes, and pore-size distributions of GO-Fe3O4 were influenced by the Fe content forming different-sized Fe3O4 between GO layers. Low Fe contents in GO-Fe3O4 increased the formation of nano-sized pores (2.0–12.5 nm) that were efficient in the adsorption of pharmaceuticals with low molecular weights (e.g., 129 kDa) or planar structures via size discrimination or inter-planar π-π interaction, respectively. As excess larger-sized pores (e.g., >50 nm) were formed on the surface of GO-Fe3O4 due to higher Fe contents, pharmaceuticals with larger molecular weights (e.g., 296 kDa) or those removed by electrostatic attraction between the adsorbate and adsorbent dominated on the GO-Fe3O4 surface. Given these observations, the surface characteristics of GO-Fe3O4 were alterable to selectively remove different pharmaceuticals in water by adsorption, and the critical factors determining the adsorption performance were discussed. These findings provide useful views on the feasibility of treating pharmaceutical wastewater, recycling valuable pharmaceuticals, or removing those with risks to public health and ecosystems.


Introduction
Pharmaceuticals are one example of contaminants of emerging concern (CECs)m referring to the chemicals which are not frequently monitored but are under examination for future regulation. These chemicals have attracted increasing concern due to their ubiquitous occurrences in the environment and potential adverse impacts on public health and aquatic ecosystems [1]. Although certain pharmaceuticals are biodegradable and some are excreted Nanomaterials 2023, 13, 2063 2 of 16 from human bodies as degradation intermediates [2], the continuously increasing use of pharmaceuticals has led to their pseudo-persistence in the environment [3]. In recent decades, many studies have investigated pharmaceutical pollution in different water environments. For example, Robert et al. analyzed the concentrations of 11 pharmaceuticals in Australia's largest inland sewage treatment plant and reported that the removal of most pharmaceuticals in the plant was incomplete [4]. Certain pharmaceuticals are known to form carcinogenic byproducts during disinfection [5,6]. A study that reviewed the current research trends on pharmaceutical pollution suggested that these chemicals are limitedly biodegradable, and integrated/hybrid technologies are recommended for their removal from wastewater [7]. Concentrations of pharmaceuticals at trace levels from ng/L to mg/L in various environmental compartments have been documented [8,9].
Pharmaceuticals include many compounds with different structural characteristics and physicochemical properties. Metformin (MET) is a medication widely used in the treatment of diabetes and has been the most-used pharmaceutical in Taiwan for many years (more than 720 tons in 2019) [5]. Its absorption uptake rate in the human body is approximately 70%, as most of the remaining portion in excreted urine is typically unchanged [10]. MET was observed in more than 90% of samples in a study that monitored the surface water quality in North China [11]. MET was detected in the influents of wastewater treatment plants in the US with high abundance, from several ng/L to less than a hundred mg/L [12]. Diclofenac (DCF) is another pharmaceutical that has a moderate absorption uptake rate (65%) and commonly remains unchanged in excreted urine [13]. It is a widely used nonsteroid anti-inflammatory drug (NSAID) and has negative influences on aquatic life with continuous exposure even at trace levels [14]. Although high DCF concentrations up to a range of mg/L were reported in rivers and wastewater [13], it is photochemically active, resulting in potential degradation in the environment [14]. Propranolol (PRO) is a betablocker medication typically used in the treatment of hypertension and angina. Over 80% of the intake dose can be excreted from the human body after metabolism [15]. As a result, PRO is frequently detected in rivers [16,17] and estuaries [18] in concentrations of up to 142 ng/L.
Graphene is a two-dimensional (2-D) allotrope of carbon which is an excellent thermal and electrical conductor with fine mechanical strength [19]. Its hydrophobic nature sometimes hinders the application of graphene in water and wastewater treatment. Oxidation of graphene surface forms graphene oxide (GO) enriched with oxygen-containing functional groups that retain the layered structures and are stably dispersed in water [20]. The hydrophilic GO has a large surface-area-to-volume ratio by being spread as layers of hexagonal ring-bound carbon structure, causing all atoms in the sheets to be exposed in water. These characteristics make this material a possible adsorbent for pollutant removal in water. Previously, we synthesized GO coated with magnetite (GO-Fe 3 O 4 ) that was capable of removing pharmaceuticals in deionized water [21] and real wastewater [22]. Compared to GO, the GO-Fe 3 O 4 composite is more readily removed from the water after adsorption by using a magnetic force. The distance between GO layers and the associated surface area was adjustable by controlling the mass ratio of Fe 3 O 4 to GO in the synthesis of the composite. It has been reported that Fe 3 O 4 strengthened the van der Waals force and π-π interaction between GO layers, preventing aggregation and thus increasing surface area and adsorption capacity [21,23].
Studies have reported efficient adsorption of organic and inorganic pollutants including pharmaceuticals onto GO-Fe 3 O 4 for their removals from the water phase [24][25][26]. However, while adsorption represents a cost-effective option with high efficiency to remove trace pollutants in water and wastewater [27], the myriad compositions in real water bodies are expected to adversely impact the performance of this technology [28]. Our previous study has observed that the natural organic matter (NOM) in municipal wastewaters reduced the adsorption of chlorpheniramine (CLP; an antihistamine medication that treats upper respiratory infection and allergic conditions in human health) on GO-Fe 3 O 4 by approximately 30% [29]. The major constituents in NOM are humic and fulvic acids that have carboxylic and phenolic groups and different molecular sizes [30]. As such, one objective of this study was to extend our previous findings and to investigate whether the size of NOM is important to affect the pharmaceutical adsorption onto GO-Fe 3 O 4 , discussing if the impact stemmed from the competition for adsorption sites in the pores of GO-Fe 3 O 4 . Additionally, as the pore volume and size distribution are adjustable by changing the Fe content in the synthesis of GO-Fe 3 O 4 [21,24], we further explored the feasibility of altering the surface characteristics of GO-Fe 3 O 4 to selectively remove different pharmaceuticals in water by adsorption and the critical factors determining the adsorption performance.

GO-Fe 3 O 4 Synthesis
The GO-Fe 3 O 4 synthesis was modified from our previously published studies [24,31]. The surface characteristics of the GO-Fe 3 O 4 composites prepared in this and other studies were similar, as discussed below, suggesting the reproducibility of the samples. Before the synthesis of GO-Fe 3 O 4 , GO was prepared. Graphite (1 g) was mixed with NaNO 3 (0.5 g) in H 2 SO 4 (23 mL) for 15 min. KMnO 4 (3 g) was slowly added for 60 min. The temperature of the solution was controlled at 35-40 • C for 2 h, followed by the addition of water (46 mL). After the color of the solution was changed from gray to brown, the solution was heated to 85-90 • C for 15 min. When the solution was cooled again, H 2 O 2 (30%; 10 mL) was added to turn the solution color yellow. The solid in the solution was filtered and mixed with HCl (10% v/v). The solid in the solution was collected again and mixed with HCl (12.5% v/v). The final solution was moved to the dialysis membrane (molecular weight cutoff (MWCO): 6000-8000, Scientific Biotech Corp., Taipei, Taiwan) and placed in deionized water. When the solution color in the membrane became black, the solution was ultrasonicated for 30 min and centrifuged (2000 rpm) for 10 min to obtain GO.
Before the synthesis of GO-Fe 3 O 4 , Fe 3 O 4 was prepared by mixing FeCl 3 and FeCl 2 with a ratio of 2.6 on a weight basis (the molar ratio of Fe 3+ to Fe 2+ was 2). GO (40 mg; dry weight) was added into different volumes of

NOM Fractionation
Two NOM sources, the SWNOM standard provided by the IHSS and the influent of a local wastewater treatment plant in southern Taiwan (LNOM), were used to investigate their interferences on pharmaceutical adsorption onto GO-Fe 3 O 4 in water. The fractionation of the two NOM sources was modified from the published procedure [32]. The NOM standards were dissolved in deionized water, followed by adjusting the pH to 7. The solution was continuously stirred overnight and filtered to remove undissolved solids. A series of Jumbosep centrifugal filters (Pall Corp., New York, NY, USA) with decreasing MWCO of 60, 18, and 6 kDa were used for NOM fractionation. Before the fractionation, the filter units were pre-rinsed with deionized water and centrifuged multiple times. The NOM solutions were added to the filter units and centrifuged with 4500 rounds per min (rpm) for 60 min. Sequential fractionation was conducted to acquire NOM fractions with >60 kDa, (18-60) kDa, (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18) kDa, and eventually <6kDa. Simply speaking, the fractionation started by using the filters with an MWCO of 60 kDa. The filtrate from a higher MWCO was used in the following stage of sequential filtration. The total organic carbon (TOC) concentrations and ultraviolet absorbance at a wavelength of 254 nm (UV 254 ) of the retentates from different stages of sequential filtration were analyzed by using a TOC analyzer (1030W, Aurora, CO, USA) and a UV-Visible scanning spectrophotometer (DR6000; HACH, Loveland, CO, USA), respectively. The specific ultraviolet absorbance (SUVA), which is the ratio of UV254 to TOC, was calculated to indicate the composition of NOM concerning the hydrophobicity, molecular characteristics, and aromaticity [33]. All NOM solutions after fractionation were stored in the dark at 4 • C.

Characterization
The surface morphology of the composites was analyzed with a scanning electron microscope (Zeiss Supra 55, Jena, Germany). The crystalline structures were determined by using an X-ray diffractometer (Bruker D8, Ettlingen, Germany) with monochromatic Cu-Kα radiation (λ = 1.542 Å). The thermal behaviors of the composites were examined by using Pyris 1 thermogravimetric analyzer (PerkinElmer, Waltham, MA, USA) at a heating rate of 10 • C/min in a temperature range from 30 • C to 875 • C. The surface zeta potentials at different pHs were investigated using the Zeta Potential measurement system (Malvern Zetasizer Nano Range, Malvern, UK). The specific surface areas were calculated by using the Brunauer-Emmett-Teller (BET) theory, and the pore size distributions and pore volumes were calculated with the N 2 adsorption-desorption isotherms based on Barrett-Joyner-Halenda (BJH) theory using an adsorption analyzer (Micromeritics ASAP 2020, Norcross, GA, USA).

Adsorption Experiment
Batch experiments were conducted in 50 mL polyethylene centrifuge tubes. In the first experiments, CLP ( Figure 1) was used as the model adsorbate. The effects of two NOM solutions with different sizes and different reaction pHs on CLP adsorption onto GO-Fe 3 O 4 were investigated. In the next experiments, three different pharmaceuticals, MET, DCF, and PRO, were selected as the target adsorbates ( Figure 1) given their different molecular sizes and structural characteristics. In all experiments, after the reactions were at equilibrium, GO-Fe 3 O 4 was removed from the water phase via centrifugation (4000 rpm for 15 min) and magnetic separation. The pharmaceutical concentrations in water were sampled and analyzed at least in duplicate and within 6 h to limit the influence of water quality variation after the experiments. The pharmaceutical concentrations in water after the experiments were used to calculate the adsorbed concentrations on the surface of GO-Fe 3 O 4 (q e ). molecular sizes and structural characteristics. In all experiments, after the reactions were at equilibrium, GO-Fe3O4 was removed from the water phase via centrifugation (4000 rpm for 15 min) and magnetic separation. The pharmaceutical concentrations in water were sampled and analyzed at least in duplicate and within 6 h to limit the influence of water quality variation after the experiments. The pharmaceutical concentrations in water after the experiments were used to calculate the adsorbed concentrations on the surface of GO-Fe3O4 (qe).

Pharmaceutical Analysis
The pharmaceutical analysis was modified from our previously published studies [5,24]. The concentrations of pharmaceuticals in the experiments were pre-treated by solid-phase extraction (SPE), followed by the analysis using ultra-high-pressure liquid chromatography coupled with a tandem mass spectrometer (UPLC-MSMS) [29]. The extraction cartridge (Oasis HLB, Waters Corp, Milford, MA, USA) used in SPE consists of a polypropylene tube (3 mL) packed with hydrophilic polymer (60 mg). Before the extraction, the column was pre-treated with ethyl acetate (3 mL), methanol (3 mL), and deionized water (3 mL) in order with a flow rate of 3 mL/min. After the column was dried, 250 mL of water sample was introduced into the SPE column by vacuum. Next, 3 mL of ethyl acetate was used to elute pharmaceuticals adsorbed in the column. 1-Hydroxypyren (100 ng/L, 10 μL) (Sigma-Aldrich, St. Louis, MO, USA) was spiked as a surrogate into the ethyl acetate extract. The UPLC (Agilent 1290 II, Santa Clara, CA, USA) was equipped with a 4.6 mm x 150 mm Poroshell 120 EC-C18 column (2.7 μm particle size; Agilent, Santa Clara, CA, USA), and 1 mL of the extract was injected. The mobile phase consisted of acetonitrile (60%, v/v) and ultrapure water (40%, v/v/) with 0.1% formic acid added. The flow rate was 0.5 mL/min. The column temperature was 40 °C. The MSMS (Agilent 5430, Santa Clara, CA, USA) was performed in the multiple reaction monitoring mode (MRM) with an ion source of electrospray ionization (ESI).

Pharmaceutical Analysis
The pharmaceutical analysis was modified from our previously published studies [5,24]. The concentrations of pharmaceuticals in the experiments were pre-treated by solid-phase extraction (SPE), followed by the analysis using ultra-high-pressure liquid chromatography coupled with a tandem mass spectrometer (UPLC-MSMS) [29]. The extraction cartridge (Oasis HLB, Waters Corp, Milford, MA, USA) used in SPE consists of a polypropylene tube (3 mL) packed with hydrophilic polymer (60 mg). Before the extraction, the column was pre-treated with ethyl acetate (3 mL), methanol (3 mL), and deionized water (3 mL) in order with a flow rate of 3 mL/min. After the column was dried, 250 mL of water sample was introduced into the SPE column by vacuum. Next, 3 mL of ethyl acetate was used to elute pharmaceuticals adsorbed in the column. 1-Hydroxypyren (100 ng/L, 10 µL) (Sigma-Aldrich, St. Louis, MO, USA) was spiked as a surrogate into the ethyl acetate extract. The UPLC (Agilent 1290 II, Santa Clara, CA, USA) was equipped with a 4.6 mm × 150 mm Poroshell 120 EC-C18 column (2.7 µm particle size; Agilent, Santa Clara, CA, USA), and 1 mL of the extract was injected. The mobile phase consisted of acetonitrile (60%, v/v) and ultrapure water (40%, v/v/) with 0.1% formic acid added. The flow rate was 0.5 mL/min. The column temperature was 40 • C. The MSMS (Agilent 5430, Santa Clara, CA, USA) was performed in the multiple reaction monitoring mode (MRM) with an ion source of electrospray ionization (ESI).

Adsorption Isotherm and Kinetics
Adsorption isotherm and kinetics are commonly used to fit the experimental adsorption data of compounds in the water phase. Two isotherm models, the Langmuir (Equation (1)) and Fruendlich isotherms (Equation (2)), were applied to determine the isotherm parameters of different pharmaceutical adsorption onto GO-Fe 3 O 4 as follows.
where C [mg/L] and q m [mg/g] represent the adsorbate concentrations in the water phase and adsorbed on the surface of the adsorbent, respectively; q max [mg/g] denotes the maxi- was studied as well. By fitting different kinetic models, the pseudo-second-order model, which is expressed as follows, yielded the best fit for the observation.
where k represents the second-order rate constant [g/mg-min]; and q t and q e denote the adsorbed concentrations onto GO-Fe 3 O 4 at the time t and equilibrium [mg/g], respectively.  Figure 2B. As shown in Figure 2C, as micro-sized aggregates of Fe 3 O 4 were dispersed and anchored between the GO layers, the distances between the GO curtains were increased. The morphology of GO-Fe 3 O 4 still showed a laminated state but became hybrid. Figure 2D-F show the images of GO-Fe 3 O 4 prepared with different Fe 3 O 4 /GO ratios in the front view. When the Fe fraction in the composite was increased, larger-sized Fe 3 O 4 aggregates caused the phenomenon of the layer-stacking GO-Fe 3 O 4 structure to become more obscure [21,24]. Figure 2G shows the X-ray diffraction (XRD) results.  [25]. These peaks were intensified by increasing the Fe fraction in the composite. A peak at 2θ 10.30 • was found in the result of GO-Fe 3 O 4 due to the interplanar spacing of GO [21]. A peak at 2θ 27.73 • representing the occurrence of FeO(OH) was observed in the profile of GO-Fe 3 O 4 and increased when the Fe 3 O 4 fraction was increased. Figure 2H shows the thermogravimetric analysis (TGA) results generated on GO-Fe 3 O 4 -2.5, GO-Fe 3 O 4 -18, and GOFe 3 O 4 -72. The percent loss in mass of GO-Fe 3 O 4 as a function of temperature was illustrated. The curves showed that maximum oxidation of carbon took place between 600 • C and 650 • C. Studies have reported similar temperature ranges for carbon oxidation [34,35]. The residual weights were associated with the metal contents of the composites. More mass losses were found as the GO content of the GO-Fe 3 O 4 composites was increased. The total mass losses of 40%, 28%, 23%, and 15% were found and corresponded with the GO contents of the composites prepared with different Fe 3 O 4 /GO ratios, respectively. The zeta potential variations of GO-Fe 3 O 4 prepared with different Fe fractions were analyzed and are shown in Figure 2H. The zeta potential of GO-Fe 3 O 4 -2.5 ranged from −35 to 0 mV. It was reported that the colloidal dispersion became stable if the zeta potential was above +30 mV or below −30 mV [36], such as in the cases of GO-   [38]. The higher surface area and the dominance of micro-/mesopores could improve the capture and removal of compounds in water by size discrimination or capillary force. Figure 3 shows the particle size distribution analyses of the composites, indicating that most of the pore sizes were below 50 nm, and~90% of the pore sizes of GO-Fe 3 O 4 -2.5 ranged from 1 to 7 nm.  1 The results listed for <2, 2-50, and >50 nm denote the volumes of micro-, meso-, and macropores in proportion to the total pore volumes of GO-Fe3O4.

Pore Blockage Effect of NOM
The successful sequential fractionation of SRNOM and LNOM to produce distinct molecular weight (MW) fractions was confirmed by TOC analysis, as shown in Figure 4A. The NOM recoveries based on the cumulative TOC concentrations through the entire sequential fractionation ranged from 77% to 95%. In Figure 4A, the fractions of SRNOM <6 kDa, (6-18) kDa, (18-60) kDa, and >60 kDa are 6%, 3%, 3%, and 89%, respectively. The fractions of LNOM < 6 kDa, (6-18) kDa, (18-60) kDa, and >60 kDa were 28%, 29%, 16%, and 28%, respectively. The larger-sized OM (>60 kDa) dominated the SRNOM, whereas the sizes of OM in the LNOM were more equally distributed. Given this observation, the SRNOM fractions >60 and <60 kDa were separated and used to investigate their impacts on the adsorption performance of GO-Fe3O4. Figure 4B reveals the pore blockage of SRNOM with different sizes (20 mg/L) on CLP adsorption onto GO-Fe3O4. The adsorbed concentration was estimated by calculating the CLP concentration adsorbed onto GO-Fe3O4. In the results, the pH effect seemed to be more critical than the NOM size for influencing the adsorption performance. Given the pKa values of CLP (3.7 and 9.2) [21] and zeta potential of GO-Fe3O4 ( Figure 2I), neutral or high pHs resulted in stronger electrostatic attraction between positive CLP and negative GO-Fe3O4, increasing the adsorption efficiency. Compared with the result of the control experiment, the adsorbed concentration dropped by up to 48% in the presence of NOM.

Selective Adsorption by Pore Size Tuning: Isotherm
While pore blocking that occurred when NOM exhibited size distributions similar to those of GO-Fe3O4-influenced CLP adsorption, the feasibility of tuning the pore size dimension of GO-Fe3O4 for selective pharmaceutical adsorption was investigated. The specific surface area, pore volume, and pore size distribution of GO-Fe3O4 were adjusted by changing the Fe3O4/GO ratio in the synthesis procedure (Table 1). Figure 5A-C reveal the adsorption of MET, PRO, and DCF onto these GO-Fe3O4 composites. The adsorbed concentrations of pharmaceuticals quickly increased and reached apparent plateaus. In the result of the GO-Fe3O4-S2.5 experiment, the maximum adsorption capacities among three pharmaceuticals were decreased in the order: PRO > DCF > MET. A similar order was  In the results, the pH effect seemed to be more critical than the NOM size for influencing the adsorption performance. Given the pKa values of CLP (3.7 and 9.2) [21] and zeta potential of GO-Fe 3 O 4 ( Figure 2I), neutral or high pHs resulted in stronger electrostatic attraction between positive CLP and negative GO-Fe 3 O 4 , increasing the adsorption efficiency. Compared with the result of the control experiment, the adsorbed concentration dropped by up to 48% in the presence of NOM. Humic acid and fulvic acid, two common species of NOM, typically exhibit negative surface charges at neutral and high pHs [39,40], and are expected to have a lower degree of interference on CLP adsorption onto GO-Fe 3 O 4 due to the electrostatic repulsion. However, the repulsion force decreased at low pHs, increasing the pore blockage effect of NOM. At a low pH (e.g., pH 3 in Figure 4B), evident competitive adsorption between CLP and NOM, notably those with MW > 60 kDa, onto GO-Fe 3 O 4 was observed. Figure 4C shows the pore blockage of LNOM with different sizes (20 mg/L) on CLP adsorption onto GO-Fe 3 O 4 . Like the observation using SRNOM, the adsorbed concentration was significantly reduced at low pHs in the absence and presence of NOM with different sizes (the q e was dropped by 2-86% from pH 11 to 3). However, besides the pH effect, it was found that the NOM between (6-18) kDa exhibited higher impacts on the adsorption at neutral and high pHs, as the influence of NOM between (6-18) kDa and (18-60) kDa became more evident at pH 3 (the adsorbed concentration was dropped by 66% and 86%, respectively). Using an equation of R min = (3V/4) 1/3 (where R min and V represent the size in nm and MW in Da, respectively) for the NOM size prediction [41], the size ranges of NOM between (6-18) kDa and (18-60) kDa were (1.2-1.7) and (1.7-2.6) nm, respectively. Our BET analysis indicated that~90% of the pore sizes of GO-Fe 3 O 4 -2.5 ranged from 1 to 7 nm ( Figure 3A). Given the similar findings between the pore size estimation and BET analysis, the adsorbed concentration was significantly affected by the presence of NOM that had size ranges close to the pore dimensions of GO-Fe 3 O 4 , especially when adsorption occurred at low pHs. Similar pore blockage effects of NOM or minerals on the adsorption of different compounds have also been reported [42,43]. Figure 4D shows the SUVA analyses of SWNOM and LNOM. The SUVA values of SWNOM < 60 and > 60 kDa were 0.57 and 3.14 L mg-C −1 m −1 , respectively. The SUVA values of LNOM fractions < 6, (6-18), , and >60 kDa were 0.07, 0.13, 0.14, and 0.67 mg-C −1 m −1 , respectively. Although the SWNOM, notably the fraction > 60 kDa, exhibited higher hydrophobicity and aromaticity, given the observations above, the pore size effect of NOM appeared to be more critical in interfering with the CLP adsorption onto GO-Fe 3 O 4 .

Selective Adsorption by Pore Size Tuning: Isotherm
While pore blocking that occurred when NOM exhibited size distributions similar to those of GO-Fe 3 O 4 -influenced CLP adsorption, the feasibility of tuning the pore size dimension of GO-Fe 3 O 4 for selective pharmaceutical adsorption was investigated. The specific surface area, pore volume, and pore size distribution of GO-Fe 3 O 4 were adjusted by changing the Fe 3 O 4 /GO ratio in the synthesis procedure (Table 1). Figure 5A Our previous study has estimated the crystalline sizes of Fe3O4 (e.g., 5.60-6.22 nm in GO-Fe3O4-2.5) using the Scherrer equation and the XRD data, suggesting that the crystalline sizes corresponded to the pore size distributions of GO-Fe3O4 [21]. As GO-Fe3O4-2.5 exhibited a relatively higher specific surface area and smaller pore size (Table 1 and Figure  4A), a higher Fe3O4/GO ratio potentially increased the interplanar spacing and largersized pore formation (e.g., GO-Fe3O4-18 or GO-Fe3O4-72 in Figure 5B,C, respectively). The MWs of MET, PRO, and DCF were 129, 259, and 296 Da, respectively. Although PRO did not have the lowest MW between the three pharmaceuticals, the fused-ring aromatic (C10H7O) structure possibly engendered its better adsorption onto GO-Fe3O4 that was mainly comprised of 2-D GO via size discrimination and/or p-p coupling with benzene rings on the surface of GO layers. In the experiments using GO-Fe3O4-18 that had a lower specific surface area, the adsorbed concentration of all pharmaceuticals dropped. When Our previous study has estimated the crystalline sizes of Fe 3 O 4 (e.g., 5.60-6.22 nm in GO-Fe 3 O 4 -2.5) using the Scherrer equation and the XRD data, suggesting that the crystalline sizes corresponded to the pore size distributions of GO-Fe 3 O 4 [21]. As GO-Fe 3 O 4 -2.5 exhibited a relatively higher specific surface area and smaller pore size (Table 1 and Figure 4A), a higher Fe 3 O 4 /GO ratio potentially increased the interplanar spacing and larger-sized pore formation (e.g., GO-Fe 3 O 4 -18 or GO-Fe 3 O 4 -72 in Figure 5B,C, respectively). The MWs of MET, PRO, and DCF were 129, 259, and 296 Da, respectively. Although PRO did not have the lowest MW between the three pharmaceuticals, the fused-ring aromatic (C 10 H 7 O) struc-ture possibly engendered its better adsorption onto GO-Fe 3 O 4 that was mainly comprised of 2-D GO via size discrimination and/or p-p coupling with benzene rings on the surface of GO layers. In the experiments using GO-Fe 3 O 4 -18 that had a lower specific surface area, the adsorbed concentration of all pharmaceuticals dropped. When the pore size was significantly increased in the case of GO-Fe 3 O 4 -72, DCF that had a larger MW was more easily adsorbed onto GO-Fe 3 O 4 and dominated the adsorption ( Figure 5C).
The Langmuir and Freundlich isotherms were employed to fit the observed data for investigating the adsorption of three pharmaceuticals onto GO-Fe 3 O 4 ( Table 2 [44]. Note that the majority of the surface area was on the GO surface. Adjusting the Fe 3 O 4 /GO ratio changed the interplanar spacing, affecting the ease of reaching the surface area. The decreasing CLP adsorption observed above was attributable to the pore blockage when GO-Fe 3 O 4 had a pore (or interplanar) size similar to that of NOM. In Figure 5, PRO and MET showed the highest (144.9 mg/g) and lowest q max (36.8 mg/g) in the GO-Fe 3 O 4 -2.5 experiment. Because of the pKa values of MET (2.8 and 11.5) [45,46] and PRO (9.5) [47,48], their surfaces had positive charges at pH 6 in the experiments [49]. DCF had a negative surface charge at pH 6 due to its pKa value of 4.2 [47,50,51]. Given the negative surface charges of GO-Fe 3 O 4 ( Figure 2I), DCF seemed to be less effectively adsorbed. However, in the experiment using GO-Fe 3 O 4 -72 that had a neutral surface charge because of high Fe content, DCF became the dominant species. The discussion here suggested that, besides the surface area, the structural dimensions (e.g., pore sizes of GO-Fe 3 O 4 and planarity of PRO) and surface charges of adsorbent and adsorbate were critical and could be tuned for selective adsorption onto GO-Fe 3 O 4 . Figure 6A-C show the experimental data with linear equations of the pseudo-secondorder kinetic models obtained by using the linear method for the sorption of three pharmaceuticals under study onto GO-Fe 3 O 4 prepared with different Fe 3 O 4 /GO ratios. The initial pharmaceutical concentrations were 90 mg/L and the reaction pH was 6. Table 3 lists the values of the pseudo-second-order kinetic model constants (k) and the amount of the pharmaceuticals adsorbed at equilibrium (q e ). The regression values suggested that there was strong positive evidence that the pharmaceutical adsorption onto GO-Fe 3 O 4 followed the pseudo-second-order kinetic expression. A pseudo-second-order kinetic model suggested the chemical adsorption of these pharmaceuticals onto GO-Fe 3 O 4 [52,53]. The initial sorption rates (k × q e 2 ) [g/mg-min] of three pharmaceuticals onto GO-Fe 3 O 4 prepared with different Fe 3 O 4 /GO ratios, when t approached zero, were calculated (Table 3). Similar to the trends in Figure 5, the initial adsorption rates of MET (from 8.56 mg/g-min in Figure 6A to negligible in Figure 6B,C) and PRO (from 30.09 in Figure 6A and 3.19 mg/g-min in Figure 6B to 1.21 mg/g-min in Figure 6C) were reduced, as the specific surface area and pore size of GO-Fe 3 O 4 were decreased and increased, respectively. Note that PRO had a much higher initial adsorption rate (30.09 mg/g min) in the experiment using GO-Fe 3 O 4 -2.5, potentially attributable to its structural planarity enhancing the adsorption onto 2-D GO layers. The increasing initial adsorption rate of DCF (from 2.66 mg/g-min in Figure 6A to 4.47 mg/g-min in Figure 6C) also corresponded well to its more efficient adsorption when GO-Fe 3 O 4 -72 that had larger pore sizes was used (Figures 5C and 6C).

Selective Adsorption by Pore Size Tuning: Kinetics
was strong positive evidence that the pharmaceutical adsorption onto GO-Fe3O4 followed the pseudo-second-order kinetic expression. A pseudo-second-order kinetic model suggested the chemical adsorption of these pharmaceuticals onto GO-Fe3O4 [52,53]. The initial sorption rates (k × qe 2 ) [g/mg-min] of three pharmaceuticals onto GO-Fe3O4 prepared with different Fe3O4/GO ratios, when t approached zero, were calculated (Table 3). Similar to the trends in Figure 5, the initial adsorption rates of MET (from 8.56 mg/g-min in Figure  6A to negligible in Figure 6B,C) and PRO (from 30.09 in Figure 6A and 3.19 mg/g-min in Figure 6B to 1.21 mg/g-min in Figure 6C) were reduced, as the specific surface area and pore size of GO-Fe3O4 were decreased and increased, respectively. Note that PRO had a much higher initial adsorption rate (30.09 mg/g min) in the experiment using GO-Fe3O4-2.5, potentially attributable to its structural planarity enhancing the adsorption onto 2-D GO layers. The increasing initial adsorption rate of DCF (from 2.66 mg/g-min in Figure  6A to 4.47 mg/g-min in Figure 6C) also corresponded well to its more efficient adsorption when GO-Fe3O4-72 that had larger pore sizes was used (Figures 5C and 6C).

Discussion
Correlation analysis was undertaken to investigate the relationships between the adsorbed concentrations of different pharmaceuticals and surface characteristics of GO-Fe 3 O 4 , as listed in Table 4. A strong negative correlation (r = −0.85) was observed between the Fe content and the specific surface area of GO-Fe 3 O 4 , whereas a higher Fe content increased the surface zeta potential (r = 0.99) and pore volume (r = 0.99). More importantly, the results showed that a lower Fe content in GO-Fe 3 O 4 increased the adsorption of MET (r = −0.67) and PRO (r = −0.94). In summary, trace Fe content creating nano-sized Fe 3 O 4 crystals that prevented GO layer stacking helped form nanopores between Fe 3 O 4 crystals and GO layers and short interplanar spacing. Smaller compounds, such as MET, or those with 2-D planar structures, such as PRO, that contain nonpolar fused rings at one end of the molecule attached to a chiral side chain could be more efficiently adsorbed onto GO layers under this circumstance by inter-planar π-π interactions or van der Waals forces [54,55]. Increasing the Fe contents enhanced the larger-size pore formation (r = 0.99 in Table 4), attributable to larger sizes of Fe 3 O 4 crystals and interplanar spacing of GO layers, and increased the surface zeta potential (r = 0.99). Under these circumstances, DCF that had a larger MW (r = 0.98) and a negative surface charge at neutral pHs (r = 0.94) became more effectively adsorbed as observed in the experiments using GO-Fe 3 O 4 -72. The amounts of pharmaceuticals were accommodated in a single molecular layer on the surface of GO-Fe 3 O 4 . The initial chemisorption rates of the pharmaceuticals with structural planarity and those with larger molecular weights were enhanced on the surfaces of GO-Fe 3 O 4 that were prepared with low and high Fe contents, respectively.

Conclusions
With the effect of the Fe content on the pore size dimensions of GO-Fe 3 O 4 and the negative influence of NOM on pharmaceutical adsorption on GO-Fe 3 O 4 , this study determined that the adsorbed pharmaceutical concentrations on the surface of GO-Fe 3 O 4 were significantly affected by NOM that had size ranges close to the pore dimensions of GO-Fe 3 O 4 . The influence of NOM was further enhanced when the adsorption reaction occurred at low pHs. The pore size dimensions of GO-Fe 3 O 4 were tunable by changing the Fe content in the synthesis to form the GO-Fe 3 O 4 composites that had different specific surface areas, zeta potentials, pore volumes, and pore size distributions. As low Fe contents in the synthesis increased the nano-sized pore formation in the GO-Fe 3 O 4 composite, the adsorption of pharmaceuticals that had smaller sizes (e.g., MET) or planar structural characteristics (e.g., PRO) was enhanced via size discrimination and inter-planar π-π interactions. Increasing the Fe content resulted in excess larger-sized pore formation in the GO-Fe 3 O 4 composite. In this case, the electrostatic attraction based on the surface charges of adsorbate and GO-Fe 3 O 4 was critical and the pharmaceuticals with larger MWs became dominant on the surface of the composite.
In conclusion, the presence of pharmaceuticals in wastewater is known as a challenge environmentally, notably due to their unknown impacts on human health and aquatic ecosystems. The findings in this study provided insight into pore blockage by NOM and the potential of tuning the pore dimensions on the surface of GO-Fe 3 O 4 for selective pharmaceutical adsorption. Although more information on producing and optimizing composites such as GO-Fe 3 O 4 for real wastewater treatment is needed, the discussion here provided useful views on the feasibility of this technology for treating pharmaceutical wastewater.